Foundational Overview of HDV

CE / CME

Hepatitis Delta in Focus: A Foundational Overview of HDV

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: December 09, 2022

Expiration: December 08, 2023

Nancy Reau
Nancy Reau, MD

Activity

Progress
1
Course Completed

References

  1. Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599. 
  2. Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:RR-8.
  3. Schillie S, Harris A, Link-Gelles R, et al. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep. 2018;67:455-458.
  4. Terrault NA, Ghany MG. Enhanced screening for hepatitis D in the USA: overcoming the delta blues. Dig Dis Sci. 2021;66:2483-2485.
  5. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398.
  6. Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020:73:523-532.
  7. Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221:1677-1687.
  8. World Health Organization. Hepatitis D. who.int/news-room/fact-sheets/detail/hepatitis-d. Accessed November 14, 2022.
  9. Da BL, Heller T, Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterol Rep (Oxf). 2019;7:231-245.
  10. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98.
  11. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. www.who.int/publications/i/item/9789241549059. Accessed November 14, 2022.
  12. Shah PA, Choudhry S, Reyes KJC, et al. An update on the management of chronic hepatitis D. Gastroenterol Rep (Oxf). 2019;7:396-402.
  13. Sriprayoon T, Mahidol C, Ungtrakul T, et al. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial. Hepatol Res. 2017;47:E161-E168.
  14. Kim GE, Da BL, Kleiner D, et al. Ten-year follow-up of long-term peginterferon-alpha treatment for chronic delta hepatitis. Presented at: American Association for the Study of Liver Diseases 2020: The Liver Meeting; November 13-16, 2020. Abstract
  15. Loureiro D, Castelnau C, Tout I, et al. New therapies for hepatitis delta virus infection. Liver Int. 2021;41(suppl 1):30-37.
  16. Bulevirtide prescribing information. Cork, Ireland: Gilead Sciences; 2020.
  17. Lampertico P, Aleman S, Blank S, et al. Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta. Presented at: The International Liver Congress 2022; June 22-26, 2022. Abstract SAT351.
  18. de Lédinghen V, Hermabessiere P, Metivier S, et al. Treatment with bulevirtide, with or withough peg-interferon, in HDV infected patients in a real-life setting; two-year results from the French multicenter early access program. Presented at: The Liver Meeting 2022; November 4-8, 2022. Abstract 28.
  19. Zoulim et al. French ANRS cohort: Preliminary real-world efficacy and safety of bulevirtide in chronic hepatitis delta. Presented at: The Liver Meeting 2022; November 4-8, 2022. Abstract 1017.
  20. A phase 2 study of peginterferon lambda, lonafarnib and ritonavir for 24 weeks: end-of-treatment results from the LIFT HDV study. Presented at: American Association for the Study of Liver Diseases 2020: The Liver Meeting; November 13-16, 2020. Abstract L08.